Remove 2017 Remove Informed Consent Remove Presentation
article thumbnail

Introductory Editorial — Critical Psychedelic Studies: Correcting the Hype

Bill of Health

In place of this purely “anti-psychedelic” critique, Langlitz notes that the present discourse of critical “anti-hype” had been initiated by “forces within ” the psychedelic field, as scholars and activists raise concerns about the ethical and political impact of psychedelic medicalization and its capitalistic roots. (I

article thumbnail

AI’s Ability to Manipulate Decision Making Requires a Moratorium on Its Use in Obtaining Consent for Biomedical Research

Bill of Health

The federal government’s commitment to assuring that participants in human subject research provide fully informed consent dates back to the U.S In 2017, Congress acted again to update the Common Rule and strengthen the provisions related to consent. While the U.S. These warnings echo those of the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2023 – January

SQA

Eudralex, Volume 4: GMP Guidelines and Annexes Revision of the EU GMP Guide Annex 11 “Computerized Systems” – Presentation of Concept Paper, 18 November 2022 On 16 November 2022, the European Medicines Agency EMA published a concept paper on the planned revision of Annex 11 “Computerized Systems.”

article thumbnail

The BFDs – The Ten Best Prescription Drug/Medical Device Decisions of 2023

Drug & Device Law

Plaintiff knew about it, too, since he signed an informed consent document mentioning it. Hrymoc was tried in late 2017. We like celebrating favorable precedent, so we also present our annual list of runners up, consisting of what we consider the next ten most favorable decisions of 2023. We’re not finished, however.

FDA 105
article thumbnail

Malarkey ? The Ten Worst Prescription Drug/Medical Device Decisions of 2023

Drug & Device Law

255 (2017) ( 2017+1 ). 21, 2017), in 2017 ), or Bausch v. Allegedly, consumers deprived of efficacy (not risk) information had their informed consent rights infringed, which in the case of persons without the genetic difference, meant that they were spared the expense of undergoing negative genetic testing.

FDA 52
article thumbnail

FDCA-Based Negligence Per Se & Informed Consent Don’t Mix

Drug & Device Law

Plaintiff allegedly suffered an injury that, according to the informed consent form he signed, was a one in 10,000 possibility. Vesoulis rejected the plaintiff’s contention that the written consent form he signed did not include a statistical presentation of the risk at issue. at *3 (citation omitted). citation omitted).

article thumbnail

Confident Learned Intermediaries Defeat Warning Causation

Drug & Device Law

H]er unequivocal position to use [the drug] or its generic equivalent to treat [the decedent] irrespective of the adequacy of [defendant’s] warning label information. . . we’ll present the rest of these cases in state-by-state style: Alabama. that he had considered the information that Plaintiff claims was wrongfully omitted. . .,

FDA 59